Osaka, Japan –April 4, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of two partial change applications by the Ministry of Health, Labour and Welfare (MHLW) for OLANZAPINE Tablets 2.5mg “SAWAI”, 5mg “SAWAI”, 10mg “SAWAI” and Fine Granules 1% “SAWAI” ... Read More
Osaka, Japan –March 26, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today announced the following organizational and personnel changes, effective April 1, 2018.
OrganizationalChanges
“Development QA” is renamed “QA Department”.
※The ... Read More
Osaka, Japan – March 20, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approval of a partial change application by the Ministry of Health, Labour and Welfare ... Read More
Osaka, Japan – February 15, 2018 – Sawai Pharmaceutical Co., Ltd. (Sawai, Head office: Osaka, Japan, President: Mitsuo Sawai) today received approvals by the Ministry of Health, Labour and Welfare for eight molecules in 19 ... Read More
Awardees Recognized for Excellence in Innovation
Maple Grove, MN – February 12, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) and the National Alliance of State Pharmacy Associations (NASPA) are proud to honor the 2017 NASPA Excellence in Innovation ... Read More
Bumetanide Tablets, USP 0.5 mg, 1 mg, and 2 mg Upsher-Smith Laboratories, LLC
Maple Grove, MN – January 30, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it has received U.S. Food and Drug Administration (FDA) ... Read More
Maple Grove, MN – January 5, 2018 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today reported that on January 3, 2018, its parent company, Japan-based Sawai Pharmaceutical Co., Ltd. (Sawai) successfully completed the sale of a 20 percent ... Read More
Maple Grove, MN – November 29, 2017 – Upsher-Smith Laboratories, LLC (Upsher-Smith) today announced that it will be exhibiting at the 71st Annual Meeting of the American Epilepsy Society (AES), December 1-5, 2017, in Washington, ... Read More
Maple Grove, MN – November 28, 2017 – Upsher-Smith Laboratories, LLC. (Upsher-Smith) today announced the launch of KLOR-CON® Powder (Potassium Chloride) for oral solution, 20 mEq. The Company received approval of an abbreviated new drug ... Read More
